The "revolution in the understanding of cancer at the molecular level" has led to dramatic responses in cancer patients to new therapies that are targeted precisely at their particular type of tumours, according to an expert.
Nov 30, 2016
0
1
A high-risk subtype of acute lymphoblastic leukemia (ALL) first identified in children is highly prevalent in adults with ALL and is associated with a poor outcome, according to an international collaboration led by St. Jude ...
Nov 21, 2016
0
0
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which ...
Nov 1, 2016
0
2
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented ...
Oct 11, 2016
0
0
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.
Oct 10, 2016
0
5
Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North ...
Oct 3, 2016
0
6
Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...
Sep 20, 2016
0
50
(HealthDay)—Postconditioning with rosuvastatin prevents myocardial ischemia-reperfusion injury in a rat model, according to a study published online Aug. 31 in Cardiovascular Therapeutics.
Sep 12, 2016
0
0
A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML ...
Sep 7, 2016
0
17
Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor ...
Aug 15, 2016
0
0
